GHK-Cu: A Matrix Peptide With a Bone-Protein Pedigree and a Dermatology Evidence Base

The short version

GHK-Cu is three amino acids — glycine, histidine, lysine — locked around a single copper ion. The copper is not an additive; it is part of the molecule, held by a chelate, a chemical grip that keeps the metal bound rather than loose.

The GHK sequence is not exotic. It occurs naturally inside the alpha-2(I) chain of type I collagen, the structural protein of bone, tendon and skin, and inside SPARC, also called osteonectin, a protein of bone matrix. That pedigree is exactly why GHK-Cu shows up in hard-tissue conversations.

What it actually does in the published record is stimulate the cells that build connective-tissue matrix, and rebalance the enzymes that break matrix down. It does that at very low concentrations, and its effect on gene expression is broad ^[14].

The controlled human evidence, though, is dermatological: wrinkles, skin firmness, hair count, and how much copper crosses a piece of skin ^{[13][15][16][17]}. No study cited here measured bone density, cartilage thickness or any joint outcome. Injectable and systemic use of GHK-Cu is unapproved and has no validated human pharmacokinetic basis at all.

What it is

GHK-Cu is a linear tripeptide, Gly-His-Lys, chelated 1:1 to a copper(II) ion. The metal is coordinated through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and the deprotonated glycine-histidine amide nitrogen, leaving the lysine side chain free. The complex is cationic, formula C14H23CuN6O4+. In cosmetic ingredient nomenclature it is Copper Tripeptide-1; other designations include prezatide copper and copper peptide GHK-Cu.

The copper is load-bearing in the literal sense. Most of the compound's documented tissue-remodelling activity depends on the copper being properly bound — the plain GHK peptide without copper does not reproduce key effects such as MMP-2 stimulation in cell studies. GHK and GHK-Cu are frequently conflated in published work, so the form used in any given study matters when reading it.

Regulatory position is split by route, and the split is sharp. Topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK with a long marketing record. Injectable, oral or otherwise systemic formulations are unapproved research chemicals with no established regulatory pathway and no FDA- or EMA-approved product for any indication. Unlike BPC-157 and TB-500, GHK-Cu is not currently named on the WADA Prohibited List as of the 2024–2025 lists, though WADA's catch-all S0 category can cover non-approved pharmacological substances, so the current list is the thing to check in any athletic-research context.

How it works

GHK-Cu acts as both a copper chaperone and a broad signalling molecule. At picomolar-to-nanomolar concentrations it directly stimulates dermal fibroblasts to synthesise collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing matrix metalloproteinases against their TIMP inhibitors — that is, telling the cell to build more matrix and to degrade less of it at the same time. The copper ion itself enables lysyl-oxidase-mediated cross-linking of collagen and elastin, which is what turns newly synthesised protein into mechanically useful tissue, and it provides superoxide-dismutase-like antioxidant activity.

At the transcriptional level the effect is unusually wide. Gene-expression analysis reports that GHK alters expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, raising 59% of the affected genes and suppressing 41%, with strong stimulation of the ubiquitin-proteasome system — 41 genes up, one down — alongside DNA-repair and antioxidant gene sets ^[14]. One caveat travels with that number and is worth carrying: the widely quoted "about 4,000 genes" figure is an extrapolation, while the table at the 50% threshold reports on the order of 2,100 genes.

The listed mechanism targets are dermal fibroblasts, keratinocytes, hair-follicle dermal papilla cells, vascular endothelial cells, alveolar and lung fibroblasts, intestinal epithelium and neurons.

That list is the crux for this file's question. Collagen synthesis, cross-linking and matrix rebalancing are the exact processes that build bone matrix and cartilage matrix — and the cells in which they were measured are skin cells. Osteoblasts and chondrocytes do not appear on the target list, because no cited study looked at them.

What the research shows

Matrix synthesis and the canonical skin review, human in vitro and clinical. GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin; plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by age 60; and topical GHK-Cu increased collagen production in 70% of treated women, against 50% for vitamin C and 40% for retinoic acid, with placebo-controlled improvements documented in skin laxity, clarity, fine lines, wrinkle depth and density ^[16].

That chondroitin sulfate mention is the single most over-read line in this compound's literature. Chondroitin sulfate is a glycosaminoglycan strongly associated with cartilage — and the synthesis measured in this work is dermal. A skin fibroblast making more chondroitin sulfate is not a chondrocyte rebuilding a joint surface, and the study did not claim otherwise.

Gene expression, human data analysis. Roughly 31.2% of human genes altered at a 50%-or-greater threshold, 59% up and 41% down, with the ubiquitin-proteasome system strongly stimulated at 41 genes up and one down, plus DNA-repair and antioxidant gene sets ^[14].

Anti-wrinkle efficacy and the delivery problem, 2025 review of human trials. The central obstacle is poor stratum-corneum permeability, clogP −2.24. Procollagen synthesis increased in 70% of GHK-Cu-treated subjects versus 50% for vitamin C and 40% for retinoic acid. Enhancement strategies under evaluation include palmitoylation — Pal-GHK, clogP 1.14 — and microneedle pretreatment, where approximately 134 nmol of GHK permeated versus none through intact skin ^[13].

Hair count, 45 men, 6 months. In men with androgenetic alopecia at Norwood-Hamilton stages II–V, a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 for placebo (p<0.05), with no adverse events in any group ^[15]. This is the strongest controlled human efficacy signal for any GHK-containing topical — and it tested a combination formulation, not pure GHK-Cu.

Skin penetration, ex vivo human skin. Copper applied as the GHK-Cu tripeptide penetrated dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10⁻⁴ cm/h; over 48 hours 136.2 ± 17.5 µg/cm² of copper permeated and 97 ± 6.6 µg/cm² was retained as a dermal depot ^[17].

What the evidence base is not. Human clinical evidence is limited to small topical dermatology trials, roughly n=13 to n=71, plus the 45-patient combination hair trial. There is no validated human pharmacokinetic data — no half-life, no Cmax, no bioavailability, no tissue distribution — for injectable or systemic GHK-Cu, so community injection protocols have no peer-reviewed basis. A large share of the foundational mechanistic and review literature originates with a single investigator and colleagues, which limits independent replication of the broader gene-expression and anti-aging claims.

Reported effects, cautions and safety

The community reports below are anecdotal, not clinical evidence — subjective, uncontrolled, mostly from skincare and research-use forums, and reproduced here without doses or concentrations.

The two most common topical benefit reports are firmer, more elastic-feeling skin after several weeks of consistent use, and softer fine lines with apparently reduced wrinkle depth over roughly six to twelve weeks, both described as gradual and cumulative. Frequently reported: better hydration and a plumper look within the first week or two, usually the earliest change noticed; smoother texture and a brighter appearance within a few weeks; and, for scalp serums often used alongside microneedling, less shedding within one to two months and thicker-looking hair over three to six months, which the community treats as a supportive add-on rather than a stand-alone hair treatment. Occasionally reported: more even tone and faded marks, and calmer-looking skin after cosmetic procedures or on healing scars. A smaller group describes reconstituting GHK-Cu for injection and reports skin-quality or recovery changes — accounts with no validated human data behind them at all, sitting well outside the documented topical use.

Adverse reports are dominated by irritation: redness, itching, stinging or a dry, tight feeling, frequently reported and repeatedly linked in community guides to starting too strong or applying too often. Also frequently reported is the complaint that the product seems to stop working or turns irritating when layered with pure vitamin C, strong acids or retinol in the same step. Occasionally reported: small breakouts or a purging phase in acne-prone users. Rarely: an effect nicknamed the "copper uglies," where skin looks duller rather than better, and temporary darkening or patchiness of pigment, mostly among people who already have melasma or stubborn dark spots. Among those using the injectable research route, injection-site redness, swelling, bruising or brief stinging is the most common complaint.

Cautions from the literature. Injectable and systemic use is unapproved and unstudied in humans, with no validated pharmacokinetic basis; the nearest data is a rat study showing the free peptide is broken down quickly in the bloodstream. Prolonged systemic copper delivery raises a theoretical concern about copper-zinc balance, which matters most for copper-handling conditions such as Wilson's disease — no human copper-toxicity case has been tied to GHK-Cu in the published record, and rodent work stayed below copper-overload thresholds. Because copper supports tyrosinase, the enzyme driving melanin production, and a laboratory study showed a copper peptide raising tyrosinase activity and melanin in pigment-cell lines, people prone to dark spots have a mechanism-based reason for caution; localised hyperpigmentation has been reported in some topical applications, including in roughly 40% of subjects in one acne-scar microneedling study. Topical irritation varies by individual and is more likely at high concentration or high frequency. Vitamin C at low pH and exfoliating acids can strip the copper from the complex, wasting both actives and stacking irritation — a documented formulation-stability issue, not folklore. If the complex does break down, the tight copper binding that normally prevents pro-oxidant behaviour is lost. And a CO2-laser post-procedure randomised trial with n=13 found no objective benefit despite higher patient satisfaction, which is a useful reminder of how far subjective impression can run ahead of measurement.

Where it fits in bone, cartilage and hard-tissue repair

GHK-Cu has the most tempting hard-tissue story of the four, and the cleanest gap between story and evidence.

The tempting part is real chemistry, not marketing. The GHK motif genuinely occurs within type I collagen — the dominant structural protein of bone and tendon — and within SPARC/osteonectin, a bone matrix protein. The compound genuinely drives collagen synthesis and lysyl-oxidase-dependent cross-linking, which is genuinely how load-bearing matrix is made ^[16]. It genuinely upregulates matrix, DNA-repair and antioxidant gene programmes ^[14].

The gap is that every controlled measurement of those effects was taken in skin. The human trials are wrinkle depth, skin density and hair count ^[13][15][16]. The penetration study is a piece of human skin on a diffusion cell ^[17]. The strongest efficacy signal came from a combination product containing 5-aminolevulinic acid, and it counted hairs ^[15]. There is no osteoblast study here, no chondrocyte study, no fracture model, no cartilage defect model, no joint-space endpoint — in any species.

So the accurate statement is narrow and worth keeping narrow: GHK-Cu acts on the machinery that connective tissue uses to build itself, and that machinery has been observed working in skin. Whether stimulating it does anything measurable to a human bone or a human joint surface is an open question that this literature has not asked.